Business
Hoth Therapeutics to Further its Research of VNLG-152 and Plans Exercise of its Option Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
Preclinical work is now underway at Weill Cornell Medicine to examine the efficacy of RAMBA in blocking acne pathogenic gene expression and carcinogenesis in
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Preclinical work is now underway at Weill Cornell Medicine to examine the efficacy of RAMBA in blocking acne pathogenic gene expression and carcinogenesis in mice\n\n\nNEW YORK, Jan. 29, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company, after further evaluation under its Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc. will exercise its option for full licensing rights of Dermatology Field to develop and commercialize therapeutic compounds for the treatment of dermatological conditions in humans.\n\n \n \n\n \nThe licensing agreement stems from results reported by UMB relating to the effect Retinoic acid metabolism blocking agents (RAMBAs) offer in treating cancer and dermatology related issues. To view the published results of the research, please click here. Furthermore, Hoth has begun its preclinical study program and anticipates sharing these results upon completion of the study.\nMr. Robb Knie, Chief Executive Officer of Hoth, commented, \"We are pleased with our research of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases over the last several months and believe that this therapeutic brings significant value to Hoth's pipeline. We look forward to working with UMB, Isoprene and Dr. Vincent Njar, lead inventor of VNLG-152 and Scientific Board Member of Hoth Therapeutics.\"\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.\nForward Looking StatementsThis press release includes \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the adv...